Trexall

Polymyositis, Uveitis, Prophylaxis against graft versus host disease + 27 more

Treatment

20 Active Studies for Trexall

Treatment for

Polymyositis

What is Trexall

Methotrexate

The Generic name of this drug

Treatment Summary

Methotrexate is a type of drug that stops the body from making certain enzymes that help with cell growth and inflammation. It is used to treat arthritis, breast cancer, and non-Hodgkin's lymphoma. It is only prescribed if other treatments have not worked or if the patient cannot tolerate those treatments. Methotrexate was approved by the FDA in 1953.

Methotrexate

is the brand name

image of different drug pills on a surface

Trexall Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Methotrexate

1953

137

Effectiveness

How Trexall Affects Patients

Methotrexate stops cells from dividing and reduces inflammation. It usually needs to be taken once a week and has a small margin of safety. Do not take methotrexate on a daily basis.

How Trexall works in the body

Methotrexate targets the enzymes that help cells reproduce, preventing them from dividing. In rheumatoid arthritis, methotrexate polyglutamates specifically inhibit an enzyme called AICART. This leads to a build-up of adenosine triphosphate and adenosine in the area around the cells, which helps reduce inflammation.

When to interrupt dosage

The amount of Trexall is contingent upon the diagnosed condition, including Uveitis, Polymyositis and nonleukemic meningeal cancer. The degree of dosage likewise differs according to the method of delivery featured in the table beneath.

Condition

Dosage

Administration

Takayasu Arteritis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Medically induced abortion

Acute Promyelocytic Leukemia

Soft Tissue Sarcoma

Chronic Graft Versus Host Disease

Leukemia

Arthritis, Juvenile

Polymyositis

Uveitis

Chemotherapy

Psoriasis

Leukemia

Lymphoma, Non-Hodgkin

Dermatomyositis

Multiple Sclerosis

Breast Cancer

Lymphoma

Crohn's Disease

Lupus

Pregnancy, Ectopic

Warnings

Trexall Contraindications

Condition

Risk Level

Notes

Non Neoplastic Condition

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Methotrexate may interact with Pulse Frequency

There are 20 known major drug interactions with Trexall.

Common Trexall Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abetimus

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Acteoside.

Aldosterone

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Aldosterone.

Trexall Toxicity & Overdose Risk

The lowest toxic dose of this drug in rats is 135mg/kg and in mice is 146mg/kg. Overdosing on this drug may cause low blood cell counts, mouth sores, nausea, vomiting, stomach ulcers, and bleeding from the digestive tract. If a patient overdoses, they should be treated with glucarpidase and should not be given leucovorin for 2 hours before or after glucarpidase.

image of a doctor in a lab doing drug, clinical research

Trexall Novel Uses: Which Conditions Have a Clinical Trial Featuring Trexall?

There are 764 active investigations into the potential of Trexall to treat Uveitis, Small Cell Lung Cancer and Soft Tissue Sarcoma.

Condition

Clinical Trials

Trial Phases

Soft Tissue Sarcoma

51 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1, Phase 3

Non-Hodgkin's Lymphoma

115 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4

Lupus

65 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1

Bladder Cancer

101 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1

Acute Lymphoblastic Leukemia

120 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4

Multiple Sclerosis

127 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1

Rheumatoid Arthritis

55 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

Hematopoietic stem cells

3 Actively Recruiting

Early Phase 1, Phase 1, Phase 2

Takayasu Arteritis

1 Actively Recruiting

Phase 2

Psoriasis

0 Actively Recruiting

Mycosis Fungoides

0 Actively Recruiting

Chemotherapy

4 Actively Recruiting

Phase 1, Phase 3, Not Applicable

Crohn's Disease

54 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1

Acute Promyelocytic Leukemia

0 Actively Recruiting

Breast Cancer

21 Actively Recruiting

Phase 2, Phase 1, Not Applicable

Sarcoma

0 Actively Recruiting

Lymphoma

4 Actively Recruiting

Phase 1, Phase 2

Gestational Trophoblastic Disease

0 Actively Recruiting

Pregnancy, Ectopic

0 Actively Recruiting

Polymyositis

3 Actively Recruiting

Phase 2, Phase 3

Trexall Reviews: What are patients saying about Trexall?

Patient Review

5/19/2010

Trexall for Rheumatoid Arthritis

I've used this treatment for two years now and it has worked well for me. I'm currently taking 8 2.5 mg doses per week, but I recently tried cutting down to 6 because I was feeling so well and didn't like the possible side effects. However, I found that my pain increased and my mobility decreased, so with my doctor's approval, I will probably go back up to 8 doses per week.

4.3

Patient Review

7/20/2009

Trexall for Rheumatoid Arthritis

I've had RA for a decade and been on methotrexate off-and-on for a couple years now. I'm currently 1.5 years into another cycle and it's helping moderately well; better than most other options available to me, at any rate. That said, it does make me tired and nauseous every dosage, which isn't ideal.

4.3

Patient Review

7/19/2013

Trexall for Inflammation of Skin and Muscles All Over the Body

I've had some indigestion, reflux and chest pains since starting this medication, but it's only been three doses.

3.7

Patient Review

10/24/2008

Trexall for Rheumatoid Arthritis

I've been taking methotrexate for nearly a year now, and I don't see any change in my current psoriasis areas. If anything, it seems like I'm getting new breakouts.

Patient Review

10/23/2012

Trexall for Rheumatoid Arthritis

Please be aware that long-term use of this drug may lead to diabetes. My husband developed blue toe syndrome and had to have a toe removed as a result.

Patient Review

10/3/2008

Trexall for Psoriasis

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about trexall

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the common side effects of methotrexate?

"Dizziness, drowsiness, headache, swollen, tender gums, decreased appetite, reddened eyes, and hair loss are all potential side effects of the medication."

Answered by AI

How long does it take for Trexall to work?

"Methotrexate requires regular laboratory monitoring in order to keep track of blood counts and the patient's liver function. The drug usually produces improvements in arthritis and other conditions within three to six weeks, although the full benefits of the drug may not be seen for 12 weeks."

Answered by AI

What is the difference between Trexall and methotrexate?

"Trexall is a brand-name medication that contains the active drug methotrexate. Methotrexate is the ingredient that makes Trexall work. Generic forms of methotrexate tablets are available, but these come in a lower strength (2.5 mg) than Trexall."

Answered by AI

What is the drug Trexall used for?

"Methotrexate is a medication that is used as a treatment for cancer, severe psoriasis, or rheumatoid arthritis. It is typically given to patients who have not responded well to other forms of treatment."

Answered by AI

Clinical Trials for Trexall

Have you considered Trexall clinical trials?

We made a collection of clinical trials featuring Trexall, we think they might fit your search criteria.

Have you considered Trexall clinical trials?

We made a collection of clinical trials featuring Trexall, we think they might fit your search criteria.

Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Steroids for Rheumatoid Arthritis

18+

All Sexes

Toronto, Canada

People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral/PO) or given as a single injection into the muscle (intramuscular/IM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience. Research Questions: 1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients? 2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction? 3. What do patients think and feel about using GCs to treat RA flares? What the Investigators Think: The investigators believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients. What the Investigators are Doing: The investigators will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either: A single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks). The main thing the investigators will look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. The investigators will also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects. In addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail. Why This Is Possible: The investigators have already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. The investigators have also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained. Why It Matters: RA flares can have a major impact on people's lives. While current treatments help control inflammation, the investigators need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.

Phase 4

Waitlist Available

Has No Placebo

Sunnybrook Health Sciences Centre (+4 Sites)